The editor of a leading psychiatry journal announced last Friday (August 25) that he was stepping down after he published a paper about a treatment for depression without disclosing that eight of nine authors--including himself--had financial ties to the company that makes the device.Charles B. Nemeroff, editor in chief of Neuropsychopharmacology, a publication of the American College of Neuropsychopharmacology (ACNP), will not serve another term as editor, the college told its members in an Email. The decision was made "in part, based on the recent adverse publicity to the journal and the ACNP," the Email said.That publicity arose after the journal's July issue carried a positive review of a vagus nerve stimulation (VNS) device made by Cyberonics, Inc, of Houston, Texas. Nemeroff was the lead author for the paper, which described VNS as a "promising and well-tolerated intervention that is effective in a subset of...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!